What was Recordati's first-half core profit (EBITDA) and how much did it increase year-on-year?

Recordati's first-half core profit (EBITDA) rose 8.8% to €540.2 million ($615.6 million).

How did Recordati's rare diseases segment perform in the first half, and what was the standout product driving growth?

Rare diseases revenue rose 17.1% to €603.9 million, with Isturisa — a treatment for Cushing's syndrome — surging 58% to €178.8 million.

Recordati first-half core profit rises 8.8% on rare diseases

Jul 28, 2026

Italian drugmaker Recordati reported an 8.8% rise in first-half core profit to €540.2 million, driven by its rare diseases segment. Its board deemed a €10.7 billion takeover offer fair, despite dissent from independent directors.

reuters

2026-07-28

Recordati first-half core profit rises 8.8% on rare diseases

Recordati first-half core profit rises 8.8% on rare diseases

FAQ